Title | High-throughput assay for G(2) checkpoint inhibitors and identification of the structurally novel compound isogranulatimide |
Publication Type | Journal Article |
Year of Publication | 1998 |
Authors | Roberge, M, Berlinck, RGS, Xu, L, Anderson, HJ, Lim, LY, Curman, D, Stringer, CM, Friend, SH, Davies, P, Vincent, I, Haggarty, SJ, Kelly, MT, Britton, R, Piers, E, Andersen, RJ |
Journal | Cancer Research |
Volume | 58 |
Pagination | 5701-5706 |
Date Published | Dec |
Type of Article | Article |
ISBN Number | 0008-5472 |
Keywords | ANTITUMOR DRUG, BHK CELLS, CAFFEINE, CELL-CYCLE CHECKPOINTS, DNA-DAMAGE, HELA-CELLS, mitosis, P34(CDC2) KINASE, P53 FUNCTION, PREMATURE, PROTEIN KINASE-C |
Abstract | Treatment of cancer cells lacking p53 function with G(2) checkpoint inhibitors sensitizes them to the toxic effects of DNA damage and has been proposed as a strategy for cancer therapy. However, few inhibitors are known, and they have been found serendipitously, We report the development of a G(2) checkpoint inhibition assay that is suitable for high-throughput screening and its application to a screen of 1300 natural extracts. We present the isolation of a new G(2) checkpoint inhibitor, the structurally novel compound isogranulatimide. In combination with gamma-irradiation, isogranulatimide selectively kills MCF-7 cells lacking p53 function. |
URL | <Go to ISI>://000077499800017 |